$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset

Eli Lilly & Co. did not rush into the immuno-oncology game like its big pharma peers, but the acquisition of newly public ARMO gives the company its most advanced IO asset via external innovation – an increased focus for Lilly's portfolio.